邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

房颤合并冠状动脉粥样硬化性心脏病的抗栓治疗策略

杨德彦,  方全

downloadPDF
文章导航 > 协和医学杂志  > 2018 >  9(2): 118-122
杨德彦, 方全. 房颤合并冠状动脉粥样硬化性心脏病的抗栓治疗策略[J]. 协和医学杂志, 2018, 9(2): 118-122. doi: 10.3969/j.issn.1674-9081.2018.02.005
引用本文: 杨德彦, 方全. 房颤合并冠状动脉粥样硬化性心脏病的抗栓治疗策略[J]. 协和医学杂志, 2018, 9(2): 118-122. doi: 10.3969/j.issn.1674-9081.2018.02.005
shu
Deyan Yang, Quan Fang. Anticoagulation Strategy in Patients with Atrial Fibrillation and Coronary Artery Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(2): 118-122. doi: 10.3969/j.issn.1674-9081.2018.02.005
Citation: Deyan Yang, Quan Fang. Anticoagulation Strategy in Patients with Atrial Fibrillation and Coronary Artery Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(2): 118-122. doi: 10.3969/j.issn.1674-9081.2018.02.005
shu

房颤合并冠状动脉粥样硬化性心脏病的抗栓治疗策略

doi: 10.3969/j.issn.1674-9081.2018.02.005

  • 中国医学科学院 北京协和医学院 北京协和医院心内科，北京 100730

详细信息
    通讯作者:

    方全  电话：010-69155068, E-mail: quanfangxjn2013@163.com

  • 中图分类号: R743.34

Anticoagulation Strategy in Patients with Atrial Fibrillation and Coronary Artery Disease

  • Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences andPeking Union Medical College, Beijing 100730, China

More Information

    摘要
  • 摘要: 房颤和冠状动脉粥样硬化性心脏病均为常见疾病。缺血性卒中和系统性血栓栓塞是房颤患者的主要不良预后，抗栓治疗可显著减少血栓栓塞事件风险；另一方面，抗血小板治疗又是冠状动脉粥样硬化性心脏病治疗的关键。当房颤患者合并冠状动脉粥样硬化性心脏病时，需要通过抗凝联合抗血小板治疗以减少卒中及缺血性心脏事件的发生。然而，联合抗栓策略会增加出血并发症的风险。如何平衡出血和血栓风险，以及如何在不同口服抗凝药物和抗血小板药物中进行选择，制定最优的抗栓方案是临床工作面临的挑战。
    Abstract: Both coronary artery disease and atrial fibrillation are common diseases. Ischemic stroke and systemic embolism are major adverse outcomes of atrial fibrillation, and antithrombotic treatment reduces the risk of thromboembolic events significantly. On the other hand, antiplatelet therapy is essential in patients with coronary artery disease. Combined antiplatelet-anticoagulant therapy is required to reduce the risk of recurrent ischemic cardiac events and stroke in patients with atrial fibrillation coexisting with coronary artery disease. However, this antithrombotic strategy is associated with an increased risk of bleeding complications. It is challenging in clinical practice to balance the risk of bleeding and thromboembolism, and to choose from oral anticoagulants and antiplatelet agents to establish an optimal strategy.
    • HTML全文
    • 参考文献(20)
  • [1] Lip GY, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EUR Observational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry[J]. Europace, 2014, 16:308-319. doi:  10.1093/europace/eut373
    [2] Kralev S, Schneider K, Lang S, et al. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography[J]. PLoS One, 2011, 6:e24964. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Open J-Gate000003875738
    [3] Bassand JP, Accetta G, Camm AJ, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF[J]. Eur Heart J, 2016, 37:2882-2889. doi:  10.1093/eurheartj/ehw233
    [4] Schmitt J, Duray G, Gersh BJ, et al. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications[J]. Eur Heart J, 2009, 30:1038-1045. doi:  10.1093/eurheartj/ehn579
    [5] Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) [J]. Eur Heart J, 2018, 39:213-260. doi:  10.1093/eurheartj/ehx419
    [6] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J, 2016, 37:2893-2962. doi:  10.1093/eurheartj/ehw210
    [7] Task Force Members, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J]. Eur Heart J, 2013, 34:2949-3003. doi:  10.1093/eurheartj/eht296
    [8] Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) [J]. Eur Heat J, 2016, 37:267-315. doi:  10.1093/eurheartj/ehv320
    [9] Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) [J]. Eur Heart J, 2018, 39:119-177. doi:  10.1093/eurheartj/ehx393
    [10] Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study[J]. Circulation, 2014, 129:1577-1585. doi:  10.1161/CIRCULATIONAHA.113.004834
    [11] 袁勋, 王文尧, 张阔, 等.冠心病合并心房颤动患者经皮冠状动脉介入治疗术后抗血小板抗凝治疗策略[J].中国循环杂志, 2015, 30:723-727. doi:  10.3969/j.issn.1000-3614.2015.08.002
    [12] 中国老年学学会心脑血管病专业委员会, 中国康复医学会心脑血管病专业委员会.稳定性冠心病口服抗血小板药物治疗中国专家共识[J].中华心血管病杂志, 2016, 44:104-111. doi:  10.3760/cma.j.issn.0253-3758.2016.02.006
    [13] 中华医学会心血管病学分会介入心脏病学组, 中国医师协会心血管内科医师分会, 血栓防治专业委员会, 等.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志, 2016, 44:382-400. doi:  10.3760/cma.j.issn.0253-3758.2016.05.006
    [14] Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study[J]. Circulation, 2012, 126:1185-1193. doi:  10.1161/CIRCULATIONAHA.112.114967
    [15] Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial[J]. Circulation, 2013, 127:634-640. doi:  10.1161/CIRCULATIONAHA.112.115386
    [16] Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial[J]. J Am Coll Cardiol, 2015, 65:1619-1629. doi:  10.1016/j.jacc.2015.02.050
    [17] Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial[J]. Lancet, 2013, 381:1107-1115. doi:  10.1016/S0140-6736(12)62177-1
    [18] Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI[J]. N Engl J Med, 2016, 375:2423-2434. doi:  10.1056/NEJMoa1611594
    [19] Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation[J]. N Engl J Med, 2017, 37:1513-1524. http://europepmc.org/abstract/MED/28844193
    [20] Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation[J]. J Am Coll Cardiol, 2013, 61:2060-2066. doi:  10.1016/j.jacc.2013.02.036
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  333
  • HTML全文浏览量:  48
  • PDF下载量:  251
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-12-29
  • 刊出日期:  2018-03-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！